Purpose Mü ller cells have important roles in the pathogenesis of diabetic retinopathy by promoting cell proliferation and inducing the production of vascular endothelial growth factor (VEGF) under hyperglycemic conditions. The objective of this study was to determine the potential mechanism of Mü ller cell proliferation and VEGF production due to high-glucose conditions. Methods Primary cultured rat Mü ller cells were incubated with medium containing variable concentrations of glucose and/or embelin, a specific inhibitor of X-linked inhibitor of apoptosis protein (XIAP), for 72 h. The proliferation of Mü ller cells was assessed by the MTT assay. The expression and/or phosphorylation of 146 proteins were assessed using protein pathway array. Results High concentrations of glucoseinduced Mü ller cell proliferation and altered expression and/or phosphorylation of 47 proteins that have been identified to have key roles in several important signaling pathways (XIAP, VEGF, HIF1a, NFkB, etc) and are involved in the regulation of cell survival, proliferation, or apoptosis. However, Mü ller cell alterations induced by highglucose conditions were counteracted by the XIAP inhibitor embelin, and 26 proteins/ phosphorylations (out of 47) were restored to their normal levels. Nine proteins, including NFkB p65, p-p38, tumor necrosis factor-a, urokinase-type plasminogen activator, CREB, IL-1b, HCAM, estrogen receptor-a, and p-Stat3, were involved in regulatory networks between XIAP and VEGF. Conclusions The current study suggests that XIAP may be a potential regulator that can mediate a series of pathological changes induced by high-glucose conditions in Mü ller cells. Therefore, embelin could be a potential agent for the prevention and treatment of diabetic retinopathy.
Introduction
Diabetic retinopathy is one of the main leading causes of vision loss in working-age people worldwide. 1 Intraocular neovascularization has been recognized to promote the development of diabetic retinopathy. 2 The vascular endothelial growth factor (VEGF) family and its receptor system, by endogenously producing vascular cytokines, contribute to angiogenesis, vasodilatation, and increased microvascular permeability. 3, 4 In recent years, the development and commercialization of anti-VEGF drugs have revolutionized the therapy of patients with intraocular neovascularization. 5 Nevertheless, the precise mechanism underlying the regulation of VEGF protein expression in intraocular angiogenesis of diabetic retinopathy remains unclear.
Mü ller cells, the principal retinal glia, have several important roles both in normal and disease states. [6] [7] [8] Reactive gliosis including hypertrophy, enlargement of soma, and proliferation are the most obvious pathological changes that occur in Mü ller cells during diabetes. 9, 10 Moreover, increased VEGF expression in Mü ller cells under hyperglycemic conditions is one of the major contributors to pathological intraocular neovascularization. 11, 12 Therefore, exposing the potential mechanism of glucoseinduced VEGF expression in Mü ller cells is essential to reveal the underlying neovascularization in diabetic retinopathy.
In this study, we investigated the potential signaling pathways and networks that are altered under highglucose conditions using protein pathway array (PPA) in an in vitro Mü ller cell model. PPA can screen the global changes both in protein expression and activation (ie, phosphorylation), and hence it is a strong tool to investigate cell proliferation, apoptosis, survival, energy metabolism, and stress response. In addition, we studied X-linked inhibitor of apoptosis protein (XIAP)-mediated cell proliferation and VEGF production by high-glucose conditions in Mü ller cells.
Materials and methods

Chemicals and drugs
A 50-mM stock solution of embelin (Sigma, St Louis, MO, USA) was prepared with dimethyl sulfoxide (DMSO; Sigma) and stored at À 20 1C before use. The stock solution was diluted using culture medium to final concentrations of 0-60 mm. D-glucose (Fisher Scientific, Fair Lawn, NJ, USA) was prepared using serum-free Dulbecco's Modified Eagle's Medium (DMEM) to final concentrations of 5, 10, 25, and 50 mM.
Mü ller cell culture
Isolation and culture of Mü ller cells from SpragueDawley (SD) rats were performed according to the methods described previously. 13 Briefly, SD rats were killed, and the eyeballs were immediately enucleated under aseptic conditions. The cornea, lens, vitreous, retinal pigmented epithelium (RPE), and nonretinal tissue were removed. Retinas were minced into 1 Â 1 mm 2 pieces and filtered through 30 mm nylon mesh after incubating with 0.25% trypsin at 37 1C for 30 min. The filtrate was then collected and centrifuged at 500 r.p.m. (or 375 Â g) for 5 min. Mü ller cells were seeded onto a 6-cm tissue culture dish in DMEM containing 20% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 2 mM sodium pyruvate, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 100 mg/ml streptomycin, and 100 U/ml penicillin at 37 1C in a humidified 5% CO 2 atmosphere. After 24 h of incubation, the DMEM was changed, and nonattached cells were discarded. Mü ller cells continued to grow in DMEM. The culture medium was replaced every 3 days. Cells were dissociated from the culture dish with 0.25% trypsin and EDTA by incubation at 37 1C. Cells at the third passage were used for the subsequent experiments. A Mü ller cell was confirmed using transmission electron microscopy, which showed characteristic cytoplasmic intermediate filaments as shown in Figure 1a .
Cell proliferation
The MTT assay (3, 4, 5-dimethylthiazol-2, 5-diphenyltetrazolium bromide; Sigma) was performed to determine the effect of high-glucose conditions and embelin on Mü ller cell proliferation. 14 Approximately 5 Â 10 3 Mü ller cells at the third passage were seeded onto each well of a 96-well plate and incubated for 24 h in serum-free DMEM. Cells were incubated in the absence or presence of high-glucose conditions or embelin for an additional 72 h in serum-free DMEM. Next, 10 ml of MTT solution at 5 mg/ml was added to each well. Cells were incubated for an additional 3 h, and the supernatant was discarded. Finally, 100 ml of DMSO was added to each well to dissolve the precipitate. Optical density was measured at a wavelength of 570 nm using an ELx800 microplate reader (Bio-Tek Instruments, Winooski, VT, USA).
Protein pathway array
Mü ller cells (1 Â 10 6 ) were cultured in 10-cm dishes in serum-free DMEM medium for 24 h. Cells were then treated with either 50 mM glucose or 50 mM glucose plus 60 mm embelin for 72 h. Total proteins from the cell culture were extracted using a 1 Â cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , and 1 mg/ml leupeptin in the presence of 1 Â proteinase inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA) and 1 Â phosphatase inhibitor cocktail (Roche Applied Science). A total of 300 ml of lysis buffer was added to each culture plate, and the cell monolayer was removed from the dish using a scraper. The lysate was sonicated twice for 15 s each time, and then it was centrifuged at 14 000 r.p.m. for 30 min at 4 1C. The protein concentration was determined using the BCA Protein Assay kit (Pierce, Rockford, IL, USA). The cell extract containing 300 mg of protein was loaded in one well across the entire width of a SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 10% acrylamide) gel as described previously. 14, 15 After electrophoretic separation, proteins were transferred electrophoretically to a nitrocellulose membrane. The membrane was then blocked for 1 h with 5% milk or 3% bovine serum albumin at room temperature. Next, the membrane was clamped with a western blotting manifold that isolates 20 channels across the membrane (Bio-Rad, Hercules, CA, USA). Two primary antibodies were added to each channel and allowed to bind to the proteins overnight at 4 1C. Different sets of antibodies were used for each membrane ( Table 1 ). The blot was washed and incubated with secondary horseradish peroxidase-conjugated antibodies (Bio-Rad) at room temperature for 1 h. The membrane was developed with chemiluminescence substrate (Immun-Star HRP Peroxide Buffer/Immun-Star HRP Luminol Enhancer; Bio-Rad), and the chemiluminescence signals were captured using the ChemiDoc XRS System (Bio-Rad). Differences in protein level were determined by densitometric scanning (Quantity One software package; Bio-Rad) and normalized using internal standards.
Western blot analysis
Mü ller cells were washed twice with cold PBS after incubation with various concentrations of glucose (5, 10, 25, and 50 mM) and/or embelin (0, 15, 30, and 60 mM) at 37 1C for 72 h. Total cellular proteins were extracted as described above. Next, 20 mg of each protein sample was fractionated by electrophoresis through a 10% SDS-PAGE, and then the proteins were transferred onto a nitrocellulose membrane. The membrane was incubated with the primary antibodies, including XIAP (1 : 250 dilution; BD Biosciences, San Jose, CA, USA) and VEGF (1 : 1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 1C overnight. The membrane was then incubated with a secondary anti-rabbit antibody conjugated with horseradish peroxidase (Amersham, Arlington Heights, IL, USA), the protein was detected using the chemiluminescence method, and chemiluminescent signals were captured using the ChemiDoc XRS System (Bio-Rad). The same membrane was then blotted using a monoclonal anti-b-actin antibody (1 : 10 000 dilution; Sigma). The signal of each protein was determined by densitometric scanning (Quantity One software package; Bio-Rad).
Signaling network analysis
To investigate the biological functional relationship among the proteins, we used Ingenuity Pathway Analysis (IPA), an internet-based program (http://www.ingenuity.com). Significantly, differentially expressed proteins (Po0.05) identified by PPA were imported to IPA for functional analysis of the canonical pathways. Based on the Ingenuity Pathway Knowledge database of known interactions from the literature, the IPA program searched already-known molecular interactions among the uploaded genes and finally generated a new network. Functional analysis identified the biological functions and/or diseases that were most significant to the data set. Statistical significance was determined by Fisher's exact test, followed by multiple testing corrections by the Benjamini and Hochberg False Discovery Rate method. Proteins were represented as nodes, and the biological relationship between two nodes was represented as a line supported by at least one reference.
Statistical analysis
All culture experiments were performed in triplicate at three independent times. Western blot experiments were repeated three independent times, and PPA was repeated twice. Data were expressed as mean ± SD. Statistical analysis of the results was performed using the Student's t-test and one-way analysis of variance. Unsupervised hierarchical clustering analysis was performed using BRB Array Tools software v.3.3.0 (http://linus.nci.nih.gov/ BRB-ArrayTools.html). A significance level was set at Po0.05.
Results
High-glucose conditions stimulated Mü ller cell proliferation
It has been previously reported that diabetic animals have more Mü ller cells, which suggests a proproliferative effect of glucose. 16 Therefore, we examined the effect of high-glucose conditions on Mü ller cell growth using the MTT assay and found a dosedependent increase of Mü ller cells after 72 h of incubation with various concentrations of glucose (up to 50 mM) (Figure 1b) .
High-glucose conditions altered the expression of regulatory proteins in Mü ller cells
To better understand the molecular mechanisms of glucose-induced Mü ller cell proliferation, we performed global screening of regulatory protein expression using powerful PPA analysis. 14, 15 Mü ller cells were treated with physiological (5 mM) and high-glucose (50 mM) conditions for 72 h, and the expressions of proteins and phosphoproteins were analyzed using PPA. Among 146 tested proteins and phosphoproteins, 108 were detected in protein samples from either the high-or normalglucose treatments (Table 1) . Of these, 47 showed a significant difference in expression between cells treated with high-glucose (50 mM) and normal-glucose (5 mM) conditions based on the paired t-test (Po0.05) and fold change (41.5) results (Figure 3a) . Forty proteins and phosphoproteins were overexpressed in high-glucosetreated cells. These 47 proteins are involved in several important signaling pathways based on IPA. These data suggest that high-glucose conditions cause a broad 
Embelin reversed the proliferation and protein expression alteration induced by high-glucose conditions
The above results demonstrated that XIAP was one of the proteins significantly upregulated after high-glucose treatment (3.33 fold, Po0.05). Next, we investigated the role of XIAP in regulating Mü ller cell survival and proliferation. XIAP prevents cells from entering apoptosis in the presence of stress by blocking the apoptosis pathway. Embelin is a small molecule that specifically inhibits XIAP. 17 Mü ller cells were incubated with various concentrations of embelin in the presence of high-glucose conditions (50 mM), and the viable cells were determined by the MTT assay. The results showed that embelin reversed the pro-proliferative effect of highglucose conditions in a dose-dependent manner (Figure 1c ). However, there was no significant increase of cell death even at 60 mM embelin, as evident by the fact that the percentage of viable cells treated with embelin was similar to those treated with normal glucose, suggesting that embelin does not significantly affect Mü ller cell apoptosis. As embelin can reverse high-glucose-induced proliferation, it is of great interest to see if embelin can correct the dysregulated signaling pathways induced by high-glucose conditions in Mü ller cells. Mü ller cells were treated with 60 mM embelin in the presence of 50 mM glucose for 72 h, and the protein expression profile was analyzed using PPA. A total of 50 proteins showed significant changes (Po0.05 and 41.5 fold changes) as compared with the controls (50 mM glucose) (Figure 2b ). Of these 50 proteins, 41 proteins were downregulated. These proteins are involved in the same pathways that were affected by high-glucose conditions based on IPA. Furthermore, the expression levels of 26 out of 50 proteins and phosphoproteins (52%), including XIAP and VEGF, were restored by embelin treatment (Figure 4a ). These data suggest that embelin can reverse the effect of high-glucose conditions on protein expression in Mü ller cells. (Figures 2a and   4a ), and inhibition of XIAP by embelin also led to a decrease of VEGF expression (Figures 2b and 4a) . To confirm this co-expression relationship, Mü ller cells were treated with increasing glucose concentrations (5, 25, and 50 mM) for 72 h, and the expression levels of VEGF and XIAP were examined using conventional western blot analysis. The results showed 42-fold increase at 25 mM glucose and 43-fold increase at 50 mM glucose of both proteins in a dose-dependent manner, respectively (Figure 3a) . This relationship was further examined by incubation of Mü ller cells with high-glucose conditions (50 mM) and various concentrations of embelin (15, 30 , and 60 mM) for 72 h. The results showed that the decrease of XIAP expression by embelin led to a decrease of VEGF expression (Figure 3b ). To further investigate how XIAP regulates VEGF expression, we generated an interactive network, with the help of IPA, using the 26 proteins that were restored to normal expression levels by embelin treatment in the presence of high-glucose conditions (Figure 4a ). The PPA results showed that nine proteins, including NFkB p65, p-p38, tumor necrosis factor-a (TNF-a), urokinase-type plasminogen activator (uPA), CREB, IL-1b, HCAM, estrogen receptor-a (ERa), and p-Stat3, were involved in a regulatory network between XIAP and VEGF (Figure 4b) . We hypothesize that XIAP may regulate VEGF mainly through the NFkB complex/p38 cascade pathways.
Discussion
Mü ller cells have an important role in the pathogenesis of diabetic retinopathy. The number of Mü ller cells is increased in patients with diabetes as a consequence of gliosis. 10 Our results unequivocally showed that high-glucose conditions stimulated Mü ller cell proliferation, consistent with a previous report. 16 Enhanced proliferation may be through dysregulation of several important signaling pathways in Mü ller cells. In the current study, the PPA and IPA data demonstrated that high-glucose conditions affected many canonical pathways including XIAP/apoptosis signaling, VEGF signaling, and cell cycle regulation, and so on. The dysregulation of these signaling pathways may collectively reduce apoptosis and enhance survival and proliferation of Mü ller cells. However, XIAP is probably the central mediator among these pathways and transmits the high-glucose signal to cell cycle progression (thus proliferation), because the inhibition of XIAP by embelin resulted in restoration of these pathways to normal levels and suppression of cell proliferation.
VEGF is one of the most potent angiogenic stimulators and vascular permeability factors. 2, 18 The Mü ller cell is an important source of VEGF in the retina, especially under hyperglycemic conditions. 11 Our study confirmed that high-glucose conditions stimulated VEGF production in Mü ller cells, suggesting a regulatory role of glucose in VEGF expression. Young et al 19 reported that intracellular VEGF protein in RPE cells was significantly increased under high-glucose conditions by regulating protein kinase C (PKC) isozymes. Wu et al 20 reported that ERK5, a member of the MAPK family, contributes to high-glucose-elevated VEGF production in the retina via the MEF2-KLF2 pathway. It is worthy to note that both PKCa and PKCb were activated via phosphorylation and that ERK was upregulated in our study.
Here we reported another mechanism by which highglucose conditions regulate VEGF expression in Mü ller cells. The expression of XIAP strongly correlated with the expression of VEGF under high-glucose conditions, and inhibition of XIAP by embelin downregulated VEGF expression, suggesting a regulatory role of XIAP in glucose-induced VEGF expression. XIAP is a member of the inhibitor of apoptosis family, which consists of intrinsic cellular regulators of apoptosis. Recent studies indicate that IAPs not only regulate caspases and apoptosis but also modulate inflammatory signaling and immunity, mitogenic kinase signaling, proliferation, and mitosis. 21 Although the exact regulatory mechanism is not clear, the IPA output suggests that a network of nine proteins (NFkB p65, p38, TNF-a, uPA, CREB, IL-1b, ERa, Stat3, and HCAM) is involved in the regulation of VEGF expression by XIAP. These data also suggest that XIAP indirectly interacts with the NFkB complex (a nuclear transcription factor with several subunits including p50/52/65), which regulates downstream proteins including p38 (a class of mitogen-activated protein kinases), HCAM (also known as CD44, a membrane receptor), TNF-a, ERa, uPA, a serine protease, and IL-1b (a member of the interleukin 1 cytokine family involved in cell proliferation, differentiation, and apoptosis). In addition, p38 regulates additional proteins including the signal transducer and activator of transcription 3 (STAT3) and cAMP response element-binding protein (CREB), which may further amplify the effect of XIAP on VEGF. Several lines of evidence support this regulatory network. For example, recent reports show that XIAP regulates ubiquitin-dependent activation of IkB kinase via its RING finger, which then activates NFkB. 21 Through the canonical and noncanonical signaling pathways, NFkB drives the expression of many downstream genes including uPA, 22 IL-1b, 23 CREB, and TNF-a. [24] [25] [26] These proteins can, in turn, increase the expression of VEGF. [26] [27] [28] A positive feedback loop may also exist between XIAP and VEGF, because it has been reported that VEGF can also enhance the expression of XIAP. 29 This positive feedback loop can further increase the production of VEGF and promote Mü ller cell proliferation.
As XIAP is critical in mediating the effect of glucose on Mü ller cell proliferation and VEGF production, it could be a potential target for treating diabetic retinopathy. Embelin, a major constituent of embelia ribes, is a cellpermeable, small molecular inhibitor of XIAP. 17 Embelin has been shown to have anti-tumor, anti-inflammatory, and analgesic properties. 30 Our study showed that embelin counteracted the glucose-related stimulatory effect on the proliferation and production of VEGF in Mü ller cells, supporting the use of embelin in the treatment of diabetic retinopathy. In fact, recent animal studies have shown that embelin has a strong antidiabetic effect in alloxan-induced diabetic rats, as evident by a reduction in fasting blood glucose levels, significant improvement in body weights, and restoration of biochemical parameters. 31 Importantly, no toxicity was observed in rats receiving embelin orally at doses of 25 and 50 mg/kg b.w.
In summary, XIAP is a central regulator that mediates high-glucose-induced pathological changes in Mü ller cells, and embelin would be an excellent candidate agent to target XIAP to prevent and treat diabetic retinopathy. Future studies will focus on investigating the molecular action of embelin and its pharmacodynamic and pharmacokinetic profiles to support future clinical trials.
Summary
What was known before K Mü ller cells have important roles in the pathogenesis of diabetic retinopathy by promoting cell proliferation and inducing the production of vascular endothelial growth factor (VEGF) under hyperglycemic conditions. The objective of this study was to determine the potential mechanism of Mü ller cell proliferation and VEGF production due to high-glucose conditions.
What this study adds
K
The current study suggests that XIAP may be a potential regulator that can mediate a series of pathological changes induced by high-glucose conditions in Mü ller cells. Therefore, embelin could be a potential agent for the prevention and treatment of diabetic retinopathy.
